Severe symptoms due to an extreme decrease in serum sodium and plasma osmolality may include one or a combination of the following: seizure, coma, and/or respiratory arrest
Commonly Reported Research Observations Injection-site redness or irritation Temporary swelling or warmth sensation at the administration site Burning or stinging during administration Temporary skin sensitivity or irritation Mild headaches Temporary fatigue or tiredness Mild nausea Temporary itching or flushing sensations Temporary blue-tinted discoloration beneath the administration area in some research settings Copper-Related Research Considerations Because GHK-Cu is a copper-binding peptide, some research protocols may monitor for: Copper- and zinc-balance variability Increased sensitivity in higher-frequency protocols Temporary skin-related response variability Individual differences in antioxidant-response pathways Research involving prolonged or higher-frequency protocols commonly investigates the inclusion of: Zinc supplementation Vitamin C supplementation alongside GHK-Curelated research models
Despite promising animal data, no published randomized controlled trials exist for BPC-157 in orthopedic patients
Studies have examined BPC-157 in models of gastric lesions, intestinal anastomosis, and inflammatory bowel conditions in animal subjects (Sikiric et al., Journal of Physiology-Paris, 2003)
Speed up tendon repair through targeted nutrition Tendons are primarily made up of the protein collagen
Mistake 2: Neglecting protein intake
